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By combining the results of a large-scale proteomic
analysis of the human transcription factor interaction
network with knowledge databases, we identified
FOXR2 as one of the top-ranked candidate proto-
oncogenes. Here, we show that FOXR2 forms a sta-
ble complex with MYC and MAX and subsequently
regulates cell proliferation by promoting MYC’s tran-
scriptional activities. We demonstrate that FOXR2 is
highly expressed in several breast, lung, and liver
cancer cell lines and related patient tumor samples,
while reduction of FOXR2 expression in a xenograft
model inhibits tumor growth. These results indicate
that FOXR2 acts with MYC to promote cancer cell
proliferation, which is a potential tumor-specific
target for therapeutic intervention against MYC-
driven cancers.INTRODUCTION
MYC is one of the best-known oncogenes; it is commonly ampli-
fied or translocated in cancers (Dang, 2012). MYC is the major
downstream target of many important pathways related to can-
cer cell growth and proliferation, which include the MAPK/ERK,
WNT, TGFb, and SHH pathways. In mammalian cells, MYC
serves as a transcription factor (TF) and binds to thousands of
promoters (Lin et al., 2012; Nie et al., 2012; Zeller et al., 2006).
Under some circumstances, such as in lymphocytes and embry-
onic stem cells, it promotes virtually all gene expression (Nie
et al., 2012). However, MYC differentially activates or represses
specific sets of direct target genes in MYC-transformed tumor
cells (Walz et al., 2014), probably via its associations with
different binding partners in cancer cells. Constitutive activation
of MYC, caused by MYC amplification and mutation, results in
uncontrolled proliferation and ultimately the development of
cancer (Beroukhim et al., 2010; Collins and Groudine, 1982;
Dalla-Favera et al., 1982; Taub et al., 1982).
MYC is involved in many cellular processes, including cell
metabolism, DNA replication, cell adhesion, differentiation, andThis is an open access article under the CC BY-Nmetastasis, mainly via its function as a transcription factor. Para-
doxically, MYC also activates apoptosis (Askew et al., 1991;
Evan et al., 1992). It can either induce or sensitize cells to
apoptosis through transcriptionally regulating a series of genes
involved in apoptosis (Dang, 1999). Tumors with MYC overex-
pression often have the activation of RAS or AKT pathway, or
mutations that disable the apoptotic program and therefore
allow these tumors to proliferate (Hoffman and Liebermann,
2008; Prendergast, 1999).
Genetic analyses have revealed that MYC overexpression,
which is commonly caused by genomic amplification, is present
in many types of human cancer (Beroukhim et al., 2010), such as
lymphoma (Dalla-Favera et al., 1982; Taub et al., 1982), breast
cancer (Bie`che et al., 1999), lung cancer (Little et al., 1983),
and liver cancer (Schlaeger et al., 2008). Transgenic mouse
models with MYC overexpression in various tissues develop tu-
mors rapidly, underscoring the potency ofMYC as an oncogene
(Dang, 2012). Intriguingly, cancer cells withMYC overexpression
are often addicted toMYC expression. Depletion or inhibition of
MYC in mouse models triggers rapid tumor regression (Boxer
et al., 2004; D’Cruz et al., 2001; Soucek et al., 2013), strongly
suggesting thatMYC is a therapeutic target for cancer treatment.
As a transcription factor, MYC is rigorously regulated via its
association with other proteins on chromatin (Blackwood and
Eisenman, 1991). MYC interacts and functions with many other
transcription factors, such as MAX (Amati et al., 1993). Most
MYC-binding proteins contain the bHLH/LZ (basic helix-loop-
helix leucine zipper) domain (Ewing et al., 2007). Through
interactions with these proteins or protein complexes, MYC
differentially regulates the transcriptional activities of its target
genes.
Our previous proteomic analysis of transcription factors re-
vealed the distinct protein-protein interaction networks on and
off chromatin (Li et al., 2015b), where we uncovered a previously
unknown interaction between MYC and FOXR2. As a member
of fork-head (FOX) transcription factor family, FOXR2 was
first identified in 2004 and it locates on human chromosome
Xp11.21 (Katoh and Katoh, 2004b). FOXR2 shares 57.7% iden-
tity with FOXR1 (Katoh and Katoh, 2004a). Similar to other FOX
family members, it contains a highly conserved forkhead domain
at its C terminus (Katoh and Katoh, 2004b). Recent large-scale
transposon mutagenesis screenings indicate that Foxr2 is aCell Reports 16, 487–497, July 12, 2016 ª 2016 The Authors. 487
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. FOXR2 Forms a Stable Complex
with MYC/MAX
(A) Prediction of transcription factors’ involvement
in tumorigenesis is based on their HCIPs identified
by TAP-MS analysis. The cancer correlations were
generated by searching the HCIP datasets of each
transcription factors in the knowledge base to es-
timate the significance of these correlations.
Transcription factor interactomes were searched
for their alteration (numbers and rates) in multiple
TCGA databases using their HCIP sets. X axis in-
dicates the relative average expression alteration
of indicated TF HCIP dataset in multiple TCGA
databases. Y axis indicates cancer correlation for
each transcription factor, estimated on the basis of
their HCIPs identified in chromatin fractions. The
size of each dot indicates the relative average
mutation rate of TF HCIP dataset in multiple TCGA
databases.
(B) Top HCIPs of FOXR1 and FOXR2 in HEK293T
cells are listed together with their NSAF values.
Baits are highlighted in blue; MYC and MAX are
highlighted in orange. All the data listed here are
statistically significant.
(C) Schematic representation of FOXR1 and
FOXR2 interactomes with top-ranked interacting
proteins. The interaction networks were visualized
using unweighted force-directed distributions.
Purple lines indicate interactions defined by the
literature. Grey lines indicate newly identified in-
teractions on the basis of the results of our proteomic study. Orange dots indicate MYC-MAX complex members reported in the literature.
(D) FOXR2 expression in HEK293T, MCF10A, and MDA-MB-468 cells were evaluated using whole proteome profiling and WB analysis with antibodies against
endogenous FOXR2.
(E) TAP-MS was performed with MDA-MB-468 cells that stably expressed SFB-tagged FOXR2, MYC, or MAX. Top-ranked interacting proteins are listed
together with their NSAF values. Baits are highlighted in blue; prey FOXR2, MYC, and MAX are highlighted in orange. All the data listed here are statistically
significant.
See also Table S1.potential tumor driver gene in malignant peripheral nerve sheath
tumors (Rahrmann et al., 2013) and medulloblastoma (Koso
et al., 2014). However, the roles of FOXR2 in human cancer
development and the underlying molecular mechanisms remain
largely unknown. In this study, we demonstrated that FOXR2 is
highly expressed in several human cancer cell lines and related
patient cancer tissues including breast, lung, and liver. FOXR2
promotes tumor growth through the activation of MYC transcrip-
tional activity. Together, these data not only demonstrated that
FOXR2 acts with MYC to promote cancer cell proliferation, but
also propose FOXR2 as a potential therapeutic target for the
MYC-driven cancers.
RESULTS
FOXR2 Forms a Stable Complex with MYC and MAX
The proteins encoded by the genes mutated in inherited genetic
disorders are likely to interact with proteins known to cause
similar disorders, which suggest the existence of disease-
related protein-protein interaction subnetworks (Gandhi et al.,
2006). Based on this theory, we decided to further analyze the
correlations between cancer and the transcription factor interac-
tomes we recently established (Li et al., 2015b). Becausemost of
tumorigenic functions of transcriptional factors rely on their tran-
scriptional activities, we analyzed the cancer correlation for each488 Cell Reports 16, 487–497, July 12, 2016bait-associated high-confidence candidate interacting protein
(HCIP) datasets in chromatin fractions (Table S1). We also per-
formed expression alteration and mutation profiling of these
HCIP datasets in multiple Cancer Genome Atlas (TCGA) data-
bases (Cerami et al., 2012; Gao et al., 2013). Combining these
datasets, we were able to characterize these transcription fac-
tors and predict their involvement in tumorigenesis (Figure 1A;
Table S1). As expected, MYC was classified as the strongest
oncogene through its transcriptional activities, and the expres-
sion of many MYC-associated proteins is highly altered in
TCGA database; other well-studied cancer-driver genes and tu-
mor suppressors, such as TP53, GLI1, and FOXO3, also passed
the threshold (Figure 1A). Surprisingly and excitingly, FOXR2was
identified as one of the strongest candidates involved in tumor-
igenesis, just next to MYC in this unbiased study (Figure 1A).
The Gene Ontology annotation indicated that FOXR2 HCIPs
identified from chromatin fraction are highly enriched in cancer
processes (p = 1.48 3 107), and their gene alteration rate is
much higher than the average rate of all the HCIP sets in this
study (Figure 1A).
We evaluated the raw interaction data and identified MYC and
MAX, as well as many MYC- or MAX-associated proteins (such
as TRRAP and p300), on the HCIP lists of FOXR2 and FOXR1
in chromatin fractions, (Figures 1B and 1C). To evaluate the rela-
tive strength of the binding, we calculated the normalized
spectral abundance factor (NSAF), in which spectral counts of
protein identified by mass spectrometry (MS) were normalized
for their theoretical numbers of tryptic peptides and represented
a percentage of the total protein recovered, as described previ-
ously (Malovannaya et al., 2010; Paoletti et al., 2006; Sardiu
et al., 2008; Zybailov et al., 2005). All the interactions listed
were statistical significant based on the Bayesian approach
described previously. MYC and MAX were identified among
the top hits in FOXR1 and FOXR2 interactomes (Figure 1B). Sur-
prisingly, although MYC and MAX were shown to be among the
top interacting proteins in FOXR2 tandem affinity purification fol-
lowed by mass spectrometry (TAP-MS), we did not identify
FOXR2 in our initial TAP-MS analysis of MYC or MAX performed
in HEK293T cells. We reasoned that this may due to the low or
restricted expression of FOXR2 in HEK293T cells, which are a
derivative of HEK293 cells that originally generated by transfor-
mation with the Adenovirus 5 genome of a likely neuroendocrine
progenitor cell contaminant in embryonic kidney prep. Thus, we
performed whole proteome profiling of HEK293T, MCF10A and
MDA-MB-468 cells. FOXR2 was not detected in any of the pro-
teome profiling experiments using HEK293T (0/20) or MCF10A
(0/8) cells, but was detected in six out of eight proteome profiling
experiments usingMDA-MB-468 cells (Figure 1D).Western anal-
ysis using FOXR2 antibody further confirmed that FOXR2 ex-
presses in MDA-MB-468 and several other breast cancer cell
lines, but not in HEK293T cells (Figure 1D). Although FOXR1
shares significant sequence similarity with FOXR2 (Katoh and
Katoh, 2004a, 2004b), FOXR1 expression was not detected in
any of the cell lines we have tested by MS or western analysis
(Figure 1D). Thus, we focused on FOXR2 in our subsequent
studies. We performed TAP-MS analysis in the chromatin frac-
tion of MDA-MB-468 cells stably expressing S, FLAG, Streptavi-
din triple-tagged (SFB)-MYC, -MAX, or -FOXR2. To extract
chromatin-bound protein complexes while minimizing the inter-
actions mediated by DNA, we treated the insoluble pellets
from the crude lysis step with TurboNuclease, which hydrolyses
both single- and double-stranded DNA or RNA to oligonucleo-
tides of one to four bases in length, to release chromatin-bound
proteins (i.e., the chromatin fraction). This step disrupts any pro-
tein-protein interactions that may be mediated by DNA. We de-
tected very little histones, HMG proteins, and other common
chromatin components in our TAP-MS results, suggesting that
we were able to eliminate most, if not all, of the non-specific
interactions mediated by DNA. As predicted, all the TAP-MS
studies identified all three proteins, as well as many known
MYC/MAX interacting proteins (Figure 1E), indicating that
FOXR2 forms a stable protein complex with MYC and MAX.
We confirmed the endogenous MYC, MAX, and FOXR2 com-
plex in MDA-MB-468 cells using immunoprecipitation (IP)-west-
ern blotting experiments. FOXR2 pulled down endogenous MAX
and MYC, mainly in the chromatin fractions, while IgG or pre-im-
mune serum failed to do so (Figure 2A). To further understand the
details of this complex formation, we performed immunodeple-
tion experiments and confirmed that these three proteins form
a stable complex, since depleting one of them reduced the levels
of the other two in the cell lysates (Figure 2B). The FOXR2-MYC/
MAX binding may be independent of MAX-MAD1 association,
since depletion of FOXR2 did not significantly change the inter-action between MAX and MAD1 (Figure 2C). We confirmed the
specificity of this interaction by demonstrating that MYC only
binds to FOXR1 and FOXR2, but not to other FOX transcription
factors (Figure 2D). We mapped the FOXR2-binding region to
the mid region (residues 120–240) of MYC (Figure 2E). We also
generated several deletion mutants of FOXR2 and showed that
the N terminus of FOXR2 is required for its binding to MYC (Fig-
ure 2F). Further analysis narrowed the domain required for MYC
binding to a 20-peptide region of FOXR2 (Figure 2G).
FOXR2 Regulates MYC Transactivation Activity and
Promotes Cancer Cell Proliferation
Because several transcriptional co-activators were also co-
purified with FOXR2 and the MYC/MAX complex, we hypothe-
sized that FOXR2 promotes MYC/MAX transactivation activity.
Indeed, using ChIP-sequencing (ChIP-seq) data on FOXR2,
MYC and MAX, we observed that 43.5% and 62.7% of FOXR2
target genes overlapped with MYC and MAX target genes
(p < 106), respectively (Figure 3A), while 64.6% and 93.8% of
FOXR2 target genes overlapped with MYC and MAX target
genes when using relatively loose cut-offs for MYC and MAX
(p < 0.0001), respectively (Figures S1A and S1B). Moreover,
similar to MYC, FOXR2 binding regions mostly localized in the
central promoter regions as demonstrated by a global analysis
of relative peak positions and highly overlapped with MYC and
MAX peaks on gene promoters (Figure 3B). These results sug-
gest that FOXR2 may modulate a fraction of MYC/MAX target
genes.We further confirmed this by chromatin immunoprecipita-
tion (ChIP) and ChIP-reChIP assays, performed with antibodies
recognizing endogenous FOXR2 and showed that FOXR2 binds
to the promoter regions of several MYC target genes, including
CCNA1, CCND1, XRCC4, XRCC6, p15, and COL1A1 in MDA-
MB-468 cells (Figures 3C, 3D, S1C, and S1D). These data indi-
cated that FOXR2 and MYC shared the similar localization on
the promoter regions for a group of downstream genes.
To further validate the functions of FOXR2 in promoting MYC
target genes and cell proliferation, we first used MCF10A cells,
which have no detectable expression of FOXR1 or FOXR2 (Fig-
ure 1D). Expression of FOXR1 or FOXR2 in MCF10A cells led
to elevated expression of the MYC target genes CCNA1 and
CCND1 (p < 0.01) and reduced the expression of the MYC-
downregulated gene COL1A1 (p < 0.05), whereas the mRNA
levels of MYC and unrelated control CTGF were largely unaf-
fected (Figure 3E). As controls, overexpression of FOXR1-DN
mutant or FOXR2-DN mutant, the two mutants that could not
bind toMYC, did not result in any obvious changes inMYC target
genes (Figure 3E). In addition, we downregulated FOXR2 expres-
sion in MDA-MB-468 cells (Figure 3F) and found reduced
expression of the MYC target genes CCNA1, CCND1, p15,
XRCC4, XRCC6, and elevated the expression of theMYC-down-
regulated gene COL1A1 (p < 0.01), whereas the mRNA levels of
MYC and unrelated control CTGF were largely unaffected (Fig-
ures 3G and S1E). We also infected MDA-MB-468/shFOXR2
cells with lentivirus to stably express wild-type FOXR2 or the
MYC-binding defective mutant FOXR2-D5 to restore the regula-
tion of FOXR2 on MYC target genes. Wild-type FOXR2 success-
fully rescued the regulation of CCNA1, CCND1, p15, XRCC4,
XRCC6, and COL1A1 (p < 0.01), while FOXR2-D5 failed to doCell Reports 16, 487–497, July 12, 2016 489
Figure 2. FOXR2 Associates with MYC/MAX on Chromatin through Its N-Terminal Region
(A) Upper panel: coIP of endogenous MAX or MYC with FOXR2 was performed with IgG or anti-FOXR2 antibody using soluble and chromatin fractions prepared
from MDA-MB-468 cells. Five percent of the corresponding cell lysate used in the IP was included as input control. Immunoblotting was conducted using the
indicated antibodies. Lower panel: coIP of endogenousMAX or MYCwith FOXR2 was performed with anti-FOXR2 antibody or pre-immune serum from the same
mouse, using chromatin fractions prepared from MDA-MB-468 and MDA-MB-468/sh-FOXR2 cells.
(B) Immunodepletion of FOXR2 and MYC performed using extracts prepared fromMDA-MB-468 cells. MDA-MB-468 cell lysates were immunoprecipitated with
FOXR2 or MYC antibodies three times. FOXR2, MYC, MAX, and b-actin levels were measured after each round.
(C) Cell lysates ofMDA-MB-468 andMDA-MB-468/sh-FOXR2 cells were immunoprecipitatedwithMYCorMAX antibodies and immunoblottedwith the indicated
antibodies.
(D) HEK293T cells were transfected with constructs encoding the indicated FOX proteins. CoIP experiments were performed using S-protein beads and blotted
with antibodies recognizing the Flag-epitope tag or endogenous MYC. Five percent of the corresponding cell lysate used in the IP was included as input control.
Only FOXR1 and FOXR2 were able to pull down endogenous MYC.
(E) Schematic diagram of MYC mutants is shown. The bHLH domain is depicted as dark gray. The mutants were: D1, (D1–D120); D2, (D120–D240); D3, (D240–
D350); and D4, (D350–D439). SFB-tagged wild-type and mutants of MYC were subjected to co-precipitation experiments with endogenous FOXR2 in MDA-MB-
468 cells. Five percent of the corresponding cell lysate used in the IP was included as input control.
(F and G) Schematic diagram of FOXR2 mutants is shown. The FOX domain appears as dark gray. The mutants were: DN, (D1–D113); DI, (D113–D192); DC,
(D192–D311); D1, (D1–D20); D2, (D20–D40); D3, (D40–D60); D4, (D60–D80); D5, (D80–D100); and D6, (D100–D113). SFB-tagged wild-type and mutants of FOXR2
were subjected to co-precipitation experimentswith endogenousMYC inHEK293T cells. Five percent of the corresponding cell lysate used in the IPwas included
as input control.so (Figure 3G). These results suggested that FOXR2 is required
for the transcription of MYC downstream target genes.
Because MYC is a well-known master regulator of cell growth
and proliferation, we determined whether FOXR2 would con-
tribute to cell proliferation through regulating MYC transcriptional
activities. Indeed, we found that FOXR1 or FOXR2 expression
strongly promoted MCF10A cell growth (p < 0.01), whereas
the expression of MYC-binding defective mutants FOXR1-DN
or FOXR2-DN failed to do so (Figure 3H). Conversely, FOXR2
knockdown in MDA-MB-468 cells led to diminished cell prolifera-
tion.MDA-MB-468-shFOXR2andMDA-MB-468-shFOXR2+SFB-490 Cell Reports 16, 487–497, July 12, 2016FOXR2(D5) cells have significantly less cell numbers after 3 days
(p < 0.01), comparing with MDA-MB-468 cells (Figure 3I). More-
over, whenwild-typeFOXR2or theMYC-bindingdefectivemutant
FOXR2-D5 was expressed inMDA-MB-468/sh-FOXR2 cells, only
wild-type FOXR2 could rescue the growth defects caused by
FOXR2 downregulation (Figure 3I). A soft agar colony formation
assay also confirmed that FOXR1 and FOXR2 have oncogenic po-
tential that is dependent on their ability to bind toMYC (Figures 3J
and 3K). Wild-type MCF10A cells did not form colony on soft
agar, which agrees with our previous results (Wang et al., 2012).
However, MCF10A cells overexpressing FOXR1, FOXR2, or
Figure 3. FOXR2 Promotes MYC Transcriptional Activities and Cell Proliferation
(A) Chromatin IP-sequencing (ChIP-seq) assay was performed in MDA-MB-468 cells using endogenous antibodies against FOXR2, MYC, or MAX. Overlap
between FOXR2 and MAX or MYC target genes were evaluated.
(B) The global analyses of relative peak positions of FOXR2 and MYC or MAX were shown.
(C) A chromatin IP (ChIP) assay was performed in MDA-MB-468 cells using FOXR2 antibody or control IgG. The recovery of MYC downstream gene promoter
regions was examined by real-time PCR. All the promoters except the control p15-distal promoter have significantly enriched in the FOXR2 (p < 0.001) but not IgG
immunoprecipitants.
(D) A ChIP-reChIP assay was performed in MDA-MB-468 cells overexpressing SFB-tagged FOXR2 using streptavidin-beads, eluted with biotin and re-immu-
noprecipitated with MYC-antibody or control IgG. The recovery of MYC downstream gene promoter regions was examined by real-time PCR. All the promoters
except the control p15-distal promoter have significantly enriched in the MYC (p < 0.001) but not IgG immunoprecipitants.
(E)MYC target gene expression profiles were evaluated by RT-PCR inMCF10A,MCF10A-FOXR1,MCF10A-FOXR2,MCF10A-FOXR1 (DN), andMCF10A-FOXR2
(DN) cells. mRNA levels were determined by real-time RT-PCR and normalized with GAPDH. CCNA, CCND1 (p < 0.01), and COL1A1 (p < 0.05) expression levels
have been significantly changed in MCF10A-FOXR1/R2 cells comparing with MCF10A cells.
(F) Knocking down FOXR2 in MDA-MB-468 cells and reconstitution with wild-type or D5 mutant of FOXR2 were confirmed by immunoblotting, as indicated.
(G) MYC target gene expression profiles were evaluated by RT-PCR in MDA-MB-468, MDA-MB-468-shFOXR2, MDA-MB-468-shFOXR2+SFB-FOXR2, and
MDA-MB-468-shFOXR2+SFB-FOXR2(D5) cells. mRNA levels were determined by real-time RT-PCR and normalized with GAPDH. CCNA, CCND1, and COL1A1
expression levels have been significantly changed in MDA-MB-468-shFOXR2 and MDA-MB-468-shFOXR2+SFB-FOXR2(D5) cells (p < 0.01), comparing with
MDA-MB-468 cells.
(H) Growth curve of MCF10A derivative cells used in (C). MCF10A-FOXR1/R2 cells have significantly more cell numbers after 3 days (p < 0.01), comparing with
MCF10A cells. Data are averages (±SD) of three independent experiments.
(I) Growth curves of MDA-MB-468 parental and derivative cells used in (E) are shown. MDA-MB-468-shFOXR2 and MDA-MB-468-shFOXR2+SFB-FOXR2(D5)
cells have significantly less cell numbers after 3 days (p < 0.01), comparing with MDA-MB-468 cells.
(J and K) Soft agar colony formation of MCF10A cells that stably expressed indicated proteins was assessed and is presented. Colony numbers: MCF10A-
FOXR1, 12.4 ± 2.2; MCF10A-FOXR1(DN), 1.4 ± 1.3; MCF10A-FOXR2, 14.2 ± 2.4; MCF10A-FOXR2(DN), 0.8 ± 0.8; MCF10A-FOXR2(D1), 9.7 ± 1.8; and MCF10A-
FOXR2(D5), 2.8 ± 1.9. The p < 0.001 between MCF10A-FOXR1 andMCF10A-FOXR1(DN), MCF10A-FOXR2 andMCF10A-FOXR2(DN), andMCF10A-FOXR2(D1)
and MCF10A-FOXR1(D5).
See also Figure S1.FOXR2(D1), which still binds to MYC, formed significantly more
colonies on soft agar (12.4 ± 2.2, 14.2 ± 2.4 and 9.7 ± 1.8, respec-
tively), whileMCF10Acells overexpressingMYCbinding defective
mutants FOXR1(DN), FOXR2(DN), or FOXR2(D5) formed signifi-cantly reduced numbers of colonies (1.4 ± 1.3, 0.8 ± 0.8, 2.8 ±
1.9, respectively) (Figures 3J and 3K). These data suggested that
FOXR1/FOXR2 promoted oncogenic transformation through their
association with MYC.Cell Reports 16, 487–497, July 12, 2016 491
Taking advantage of the knowledge of the collaboration be-
tween MYC and RAS in promoting oncogenic transformation,
we overexpressed FOXR2, MYC, RAS, or any two together in
MCF10A cells, to evaluate whether FOXR2 and MYC function
in the same oncogenic pathway. Overexpression of FOXR2,
similar to that of MYC, led to 70% reduction in cell number
following the initial infection (96 hr post-infection), which was
likely due to MYC-induced apoptosis. An interesting observation
was that cells overexpressing FOXR2 plus RAS, but not FOXR2
plus MYC, rescued this cell death phenotype (Figure 4A).
Western analysis using cleaved Caspase-3 antibody as a
marker for apoptosis confirmed elevated apoptosis in MCF10A
cells infected by retroviruses overexpressing FOXR2 or MYC,
while MCF10A cells expressing RAS with FOXR2 or MYC
partially blocked this induced apoptosis (Figure 4A). Moreover,
MCF10A cells expressing FOXR2 with RAS formed significantly
more colonies on soft agar than did MCF10A cells expressing
FOXR2, MYC, or both (Figure 4B). We knocked downMYC using
shRNA in MCF10A cells and then infected these cells with retro-
viruses overexpressing FOXR2. The FOXR2-induced apoptosis
was reduced in MCF10A-shMYC cells (Figure S2A). Moreover,
overexpression of tagged FOXR2 in MCF10A-shMYC cells failed
to induce colony formation on soft agar (Figure S2B). These
results indicate that FOXR2-induced apoptosis and transforma-
tion are MYC-dependent. These findings support the idea that
FOXR2 and MYC function in the same oncogenic pathway.
FOXR2 downregulation also led to reduced cell proliferation in
MDA-MB-468 cells, as measured by Ki-67 staining (81% versus
51%; p < 0.01) and bromodeoxyuridine (BrdU) incorporation
(77% versus 42%; p < 0.01) (Figure 4C). Moreover, both tumor
size and tumor weight were significantly reduced inmice injected
withMDA-MB-468/sh-FOXR2 cells compared with those in mice
injected with control MDA-MB-468 cells (32.2 ± 11.9 mg versus
651.7 ± 342.0mg; p < 0.01) (Figure 4D). Reconstitution with SFB-
tagged wild-type FOXR2, but not MYC binding defective mutant
FOXR2(D5), fully rescued tumor growth (751.1 ± 287.9mg versus
115.4 ± 105.5 mg; p < 0.001) (Figure 4D). Together, these data
suggest that FOXR2 acts with MYC and promotes cancer cell
proliferation both in vitro and in vivo.
FOXR2 Was Overexpressed in Cancer Cell Lines and
Patient Tumor Samples
We tested 13 breast cell lines, as well as HEK293T cells as the
negative control. Indeed, we found that FOXR2 was not ex-
pressed in the three normal human breast epithelial cell lines
we tested (MCF10A, HMLE, and HBL100) but was detectable
in 5 of the 11 (45%) breast cancer cell lines we assayed
(ZR75.1, T47D, MCF-7, MDA-MB-468, and SUM52PE) (Figures
4E and S2C). Moreover, FOXR2 was not expressed in the two
normal human lung cell lines we tested (human bronchial epithe-
lial cells NHBE and WI-38, which are lung-derived fibroblasts)
but was detectable in all the six lung cancer cell lines we assayed
(A549, H460, H1650, PC9, H2279, and H358) (Figure 4F). Simi-
larly, FOXR2 was not expressed in the two normal human liver
cell lines we tested (THLE-2 and THLE-3) but was detectable
in three of the six (50%) liver cancer cell lines we assayed
(HepG2, Huh7, and SNU-398) (Figure 4G). MG132 treatment
could stabilize FOXR2 in HBL100 cells but not MCF10A cells492 Cell Reports 16, 487–497, July 12, 2016(Figure S2D), indicating that FOXR2 may be regulated, at least
in some cases, via a ubiquitination- and proteasome-dependent
pathway. These data suggest that FOXR2 is overexpressed in
human cancer cell lines. Given the potential role of FOXR2 in pro-
moting cell proliferation, as demonstrated above, we further
analyzed FOXR2 expression by immunohistochemical analysis
in human primary tumor samples. We first confirmed the speci-
ficity of our FOXR2 antibody in paraffin-embedded cell lines (Fig-
ure 5A). FOXR2 antibody only stained MCF-7 and MDA-MB-468
cells but not MCF10A cells, which is consistent with western
blotting results using these cell lines (Figures 1D, 4E, and 5A).
Knocking down FOXR2 in MDA-MB-468 cells greatly reduced
the staining (Figure 5A), indicating that the cross-reaction of
this FOXR2 antibody is quite limited. Thus, we used this antibody
to examine the expression of FOXR2 in 273 breast, 145 lung, and
210 liver tumor or normal tissue samples (Figures 5B–5D).
FOXR2 was positively stained in only 6.3% of normal breast tis-
sue samples (2 of 32), but 14.3% of stage I (3 of 21), 40.6% of
stage II (73 of 180), and 57.5% of stage III/IV (23 of 40) malignant
breast tumor samples (Figures 5B, 5E, and 5F). It was stained
positively in only 9.1% of normal lung tissue samples (2 of 22),
but in 33.3% stage I (16 of 48), 46.7% stage II (14 of 30), and
34.9% of stage III/IV (15 of 43) malignant lung tumor samples
(Figures 5C, 5E, and 5F). It was stained positively in 16.7% of
normal liver tissue samples (2 of 12), but 45.8% in malignant liver
tumor samples (Figures 5D–5F). Therefore, we conclude that
FOXR2 is frequently overexpressed in breast, lung, and liver can-
cers and may contribute to the proliferation of these cancers.
DISCUSSION
In this study, we revealed that FOXR2 is overexpressed in breast,
lung and liver cancers and plays a role in MYC-dependent gene
transcription and cell proliferation. The potential role of FOXR2
as an oncogene was independently reported (Rahrmann et al.,
2013), in which the authors identified Foxr2 as a proto-oncogene
in mice and showed that it is overexpressed in human malignant
peripheral nerve sheath tumors and required for tumor prolifera-
tion. Therefore, it is likely that FOXR2 overexpression contributes
to human tumor growth.
We found that a subset of cancer cell lines and tumor samples
showed FOXR2 upregulation (Figures 4E–4G and 5). Together
with the observations that FOXR2 binds to MYC (Figures 1
and 2) and activates MYC-dependent gene transcription (Fig-
ure 3), we reason that targeting FOXR2 may be a viable option
for treating these cancers. Furthermore, we speculate that
agents that disrupt FOXR2 or FOXR2-MYC interaction in adult
tissues may have mild or limited side effects compared with
agents that directly target MYC, since FOXR2 is only expressed
in cancer cell lines and tumor samples (Figures 4E–4G and 5),
and therefore hold great therapeutic potential.
FOXR1 shares significant sequence homology with FOXR2
(Katoh and Katoh, 2004a, 2004b) and also interacts with MYC/
MAX (Figures 1B, 1C, and 2D). Overexpression of FOXR1 leads
to similar effects as that of FOXR2 (Figures 3E, 3H, and 3J).
However, unlike FOXR2, FOXR1 protein was not detectable in
any breast, liver, or lung cell lines we tested by MS or western
analysis (Figure 1D). These data suggest that FOXR2 is likely a
Figure 4. FOXR2 Facilitates MYC’s Activities and Promotes Tumor Proliferation Both In Vitro and In Vivo
(A) MCF10A cells were infected in 6-well plates with retroviruses encoding RAS, MYC, FOXR2, or any two together. Cells were counted after 96 hr of infection.
Normalized cell numbers are presented. Data are averages (±SD) of three independent experiments. Cell lysates of each cell lines were immunoblotted with the
indicated antibodies.
(B) Soft agar colony formation of MCF10A cells that stably expressed the indicated proteins was assessed and is presented.
(C) Ki-67 and BrdU staining of MDA-MB-468 and MDA-MB-468/sh-FOXR2 cells was performed as indicated. The percentages of positive cells are summarized
on the right. **p < 0.01.
(D) Xenograft tumor growth studies. MDA-MB-468 and MDA-MB-468/sh-FOXR2 cells (5 3 106) were resuspended in 100 ml of Matrigel diluted with PBS at 1:1
ratio and injected subcutaneously into left and right flanks of ten anesthetized 6- to 8-week-old female BALB/c nude mice, respectively. MDA-MB-468/sh-
FOXR2+SFB-FOXR2 and MDA-MB-468/sh-FOXR2+SFB-FOXR2(D5) cells (5 3 106) were resuspended in 100 ml of Matrigel diluted with PBS at 1:1 ratio and
injected subcutaneously into left and right flanks of ten anesthetized 6- to 8-week-old female BALB/c nude mice, respectively. Starting from the day 0, the tumor
weight and size were measured bi-weekly. Mice were euthanized after 8 weeks of injection. The tumors were excised, photographed, and weighed. ***p < 0.001.
(E) Immunoblotting of FOXR2 in normal and breast cancer cell lines, with HEK293T cells as the negative control.
(F) Immunoblotting of FOXR2 in normal and lung cancer cell lines.
(G) Immunoblotting of FOXR2 in normal and liver cancer cell lines.
See also Figure S2.
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Figure 5. FOXR2 IsOverexpressed inCancers
(A) Immunohistochemical staining of breast cell lines
was performed using FOXR2 antibody to validate
the specificity of our anti-FOXR2 antibody.
(B–E) FOXR2 staining of normal and tumor tissue
microarrays of breast (B), lung (C), and liver (D)
samples. The data were summarized in (E), with
case numbers and percentages.
(F) Bar graph summary of data presented in (B)–(E).
*p < 0.05, **p < 0.01, ***p < 0.001.proto-oncogene in these cancers, while FOXR1 expression may
be more restricted to early stages of development as previously
reported (Schuff et al., 2006).
EXPERIMENTAL PROCEDURES
Western Blotting, Immunoprecipitation, Immunostaining, and
Immunohistochemistry Assays
Whole-cell lysates were prepared by lysing cells with NETN buffer (20mMTris-
HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, and 0.5% Nonidet P-40) on ice for
30 min and then boiling them in 23 Laemmli buffer (Wang et al., 2015). To
extract chromatin-bound protein complexes while minimizing the interactions
mediated by DNA, we treated the insoluble pellets from the crude lysis step
with TurboNuclease, which hydrolyses both single- and double-stranded
DNA or RNA to oligonucleotides of one to four bases in length, to release chro-
matin-bound proteins (i.e., the chromatin fraction). This step disrupts any pro-
tein-protein interactions that may be mediated by DNA. We used the same
protocol to prepare lysates for our co-immunoprecipitation (coIP) experiments
in chromatin fractions. Lysates were subjected to SDS-PAGE, followed by494 Cell Reports 16, 487–497, July 12, 2016immunoblotting with antibodies against various pro-
teins, including MYC, FOXR2, GFP, GAPDH, MAD1
(Santa Cruz Biotechnology), cleaved Caspase-3,
MYC,MAX (Cell Signaling), FOXR2 (Abcam), b-actin,
FLAG (Sigma), and histone H3 (Upstate). Rabbit
polyclonal antibody against human FOXR2 (resi-
dues 1–311) was generated by immunizing rabbits
(Cocalico Biologicals) with GST-FOXR2 fusion pro-
tein and affinity purified before being used for west-
ern blotting, ChIP-seq and immunohistochemistry
(IHC) analyses.
For immunoprecipitation and co-immunoprecipi-
tation assays, a total of 1 3 107 cells were lysed
with NETN buffer on ice for 30 min and fractionized
as described above. The lysates were then incu-
bated with 20 ml conjugated beads (for SFB-tagged
pull-down) for 2 hr at 4C; or incubated with anti-
bodies against endogenous proteins for 1 hr at
4C, followed by adding 20 ml of protein A/G agarose
and incubated for 2 hr at 4C. Beads were washed
three times with NETN buffer and boiled in 23
Laemmli buffer.
For immunostaining assays, cells cultured on cov-
erslips were washed with PBS, fixed with 3% para-
formaldehyde for 20 min, and permeabilized with
0.5% (v/v) Triton X-100 solution for 5min. Coverslips
were washed with PBS and immunostained with pri-
mary antibodies in 5% goat serum for 60 min. Cells
were then washed and incubated with rhodamine-
or fluorescein isothiocyanate (FITC)-conjugated
secondary antibodies for 60 min, and nuclei were
stained with 1 mg/ml DAPI. Slides were mounted
and visualized using a Nikon ECLIPSE E800 fluores-
cence microscope with a Nikon Plan Fluor 403 oilobjective lens (numerical aperture 1.30) at ambient temperature. Cells were
photographed using a SPOT camera (Diagnostic Instruments).
For the IHC assays, 53 106MCF10A,MCF-7,MDA-MB-468, andMDA-MB-
468/sh-FOXR2 cells were trypsinized, PBS-washed, paraffin-embedded, and
sliced to make slides. All of the human breast, liver, and lung cancer tissue mi-
croarrays were purchased from US Biomax. The slides were deparaffinized
and rehydrated and blocked for 30min in 1%hydrogen peroxide andmethanol
to remove endogenous peroxidase activity. After antigen retrieval, slides were
blocked in 5% goat serum in PBS and incubated overnight with anti-FOXR2
antibodies diluted (1:200) in blocking buffer. After being washed with PBS,
slides were incubated in secondary antibodies diluted (1:200) in blocking
buffer for 3 hr, developed with 3,30-diaminobenzidine (DAKO), and re-stained
with hematoxylin for 30 s. Slides were mounted and visualized using the same
microscope and lens.
Tandem Affinity Purification, Mass Spectrometry, and Data Analysis
Tandem affinity purification and mass spectrometry analysis were carried out
as previously described (Elias and Gygi, 2007; Li et al., 2015a, 2015b; Shev-
chenko et al., 1996). To generate HCIP lists, we applied a modified SAINT
algorithm, which uses a collection of TAP-MS results that follow the same
protocol as the control group (Li et al., 2015b; Wang et al., 2014; Xu et al.,
2014). We kept the same SAINT Score >0.80 interactions as on the HCIP
list. To calculate the normalized spectral abundance factor (NSAF), protein re-
sults from MS sequencing were converted to NCBI gene identifiers. Spectral
counts of these gene products were then normalized for their theoretical
numbers of tryptic peptides and represented a percentage of the total protein
recovered, as described previously (Malovannaya et al., 2010; Paoletti et al.,
2006; Sardiu et al., 2008; Zybailov et al., 2005). The probability of interactions
within and between complexes is computed solely based on NSAFs using
Bayesian approach. Only the statistical significant results were presented.
We searched the proteins identified in FOXR1 and FOXR2 TAP-MS in the pro-
tein-protein interaction knowledge databases to identify the interactions
reported in the literature. The databases we used were BioGrid (http://
thebiogrid.org) (Stark et al., 2006), STRING (http://string-db.org) (von Mering
et al., 2003), BIND (Bader et al., 2003), DIP (http://dip.doe-mbi.ucla.edu) (Xe-
narios et al., 2000), and HPRD (http://www.hprd.org) (Prasad et al., 2009).
The interaction networks were visualized by Cytoscape software (Smoot
et al., 2011) using unweighted force-directed distributions. The protein points
were placed based on the number of shared interacting proteins. The dis-
tances between different points have no correlation with the binding affinities
between proteins.
ChIP, ChIP-reChIP, ChIP Sequencing, and Genomic Data Analysis
For the ChIP assay, 1 3 106 MDA-MB-468 cells (1 3 107 cells for ChIP
sequencing) were cross-linked with 1% formaldehyde in growth medium for
10 min. Cross-linking was terminated by the addition of glycine to a final con-
centration of 125mM and incubation at 37C for 10 min. Cells were rinsed with
cold PBS, harvested in 200 ml of SDS lysis buffer supplemented with protease
inhibitor mixture (Roche Applied Science) and 1 mM phenylmethylsulfonyl-
fluoride (PMSF) per 13 106 cells, and sonicated to shear the DNA to yield frag-
ments of 500 base pairs (bp) or less. Samples were then diluted with 9 vol of
ChIP dilution buffer before being precleared for 1 hr with 40 ml of a mixture
of protein A/G agarose and salmon sperm DNA. Approximately 5 mg of
FOXR2, MYC, or MAX antibody or mouse normal immunoglobulin (IgG) were
added to the precleared supernatant and incubated for 1 hr at 4C. Forty mi-
croliters of protein A/G agarose were added, and the mixture was incubated
overnight at 4C. Washes were sequentially performed with low-salt buffer,
high-salt buffer, LiCl buffer, and twice with TE buffer. Immunoprecipitates
were eluted in 500 ml of elution buffer (1% SDS, 0.1 M NaHCO3), followed
by the addition of NaCl (20 ml). Crosslinking was reversed by overnight incuba-
tion of samples at 65C and treatment with protease K (Sigma) for 2 hr at 45C.
The recovered DNA was extracted with phenol-chloroform and precipitated
with ethanol. Quantification was performed by real-time PCR with the My IQ
real-time PCR detection system and an IQ SYBR Green Supermix (Bio-Rad).
Control IgG and input DNA values were used to normalize values from ChIP re-
covery. For the ChIP-reChIP assay, 1 3 107 MDA-MB-468/SFB-FOXR2 cells
were processed followed the same ChIP protocol, but used 50 ml streptavidin
beads for the initial pull-down. The beads were washed with NETN buffer three
time and immunoprecipitates were eluted twice in 150 ml NETN buffer contain-
ing 2 mg/ml biotin. The elutes were then diluted with 9 vol of ChIP dilution
buffer before adding 10 mg of MYC antibody or mouse normal immunoglobulin
(IgG) for the secondary immunoprecipitation.
ChIP sequencing was performed in HEK293T cells with two biological rep-
licates. Samples were sequenced using Illumina HiSeq, and raw reads were
mapped to human reference genome (hg19). Peaks were selected using
MACS in Galaxy and annotated with PAVIS (Huang et al., 2013; Langmead
et al., 2009; Zhang et al., 2008). Datasets were analyzed in Galaxy andmapped
to genes using PAVIS, with 5,000 to +1,000 TSS windows.
In Vivo Xenograft Study
All animal experiments were performed in accordance with a protocol
approved by the Institutional Animal Care and Use Committee (IACUC) of
the M.D. Anderson Cancer Center. MDA-MB-468 and MDA-MB-468/sh-
FOXR2 (5 3 106) cells were resuspended in 100 ml of Matrigel diluted with
PBS at 1:1 ratio and injected subcutaneously into left and right flanks of ten
anesthetized 6- to 8-week-old female BALB/c nude mice, respectively. Simi-larly, 5 3 106 MDA-MB-468/sh-FOXR2+SFB-FOXR2 and MDA-MB-468/sh-
FOXR2+SFB-FOXR2(D5) cells were resuspended in 100 ml of Matrigel diluted
with PBS at 1:1 ratio and injected subcutaneously into left and right flanks of
ten anesthetized 6- to 8-week-old female BALB/c nude mice, respectively.
Starting from the day 0, the tumor weight and size were measured bi-weekly.
Mice were euthanized after 8 weeks of injection. The tumors were excised,
photographed, and weighed.
Soft Agar Colony Formation Assay
Cells (1 3 103) were added to 1.5 ml of growth medium with 0.2% agar and
layered onto 2 ml of 0.5% agar bed in 6-well plates. Medium was replenished
every 3 days for 30 days. Resulting colonies were fixed and stained with Crys-
tal Violet. The numbers of colonies were counted with a GelDoc with Quantity
One software (Bio-Rad).
Statistical Analysis
All experiments were repeated at least three times. Data were analyzed by
Pearson c2 analysis (for IHC) and the Student’s test (for all other experiments).
A p value of <0.05 was considered statistically significant.
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through accession number GEO: GSE81381.
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